|Bid||9.89 x 1300|
|Ask||9.90 x 2000|
|Day's Range||9.55 - 9.93|
|52 Week Range||3.21 - 10.77|
|PE Ratio (TTM)||-9.91|
|Earnings Date||Mar 7, 2017 - Mar 13, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||11.50|
Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at two upcoming conferences being held in New York.
In 2Q17, Evomela reported revenues of ~$10.1 million, which is the highest quarterly revenue figure reported by the drug since its commercial launch in 2016.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Spectrum Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SPPI-US. Comparing the performance and risk of Spectrum Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)